var data={"title":"Polysaccharide-iron complex: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polysaccharide-iron complex: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6800?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polysaccharide-iron-complex-drug-information\" class=\"drug drug_general\">see &quot;Polysaccharide-iron complex: Drug information&quot;</a> and <a href=\"topic.htm?path=polysaccharide-iron-complex-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polysaccharide-iron complex: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211213\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>EZFE 200 [OTC];</li>\n      <li>Ferrex 150 [OTC];</li>\n      <li>Ferric x-150 [OTC];</li>\n      <li>iFerex 150 [OTC];</li>\n      <li>Myferon 150 [OTC];</li>\n      <li>NovaFerrum 125 [OTC];</li>\n      <li>NovaFerrum 50 [OTC];</li>\n      <li>NovaFerrum Pediatric Drops [OTC];</li>\n      <li>Nu-Iron [OTC];</li>\n      <li>PIC 200 [OTC] [DSC];</li>\n      <li>Poly-Iron 150 [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1031838\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Iron Salt</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49161081\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Doses expressed in terms of <b>elemental</b> iron.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adequate Intake (AI): </b>Oral: 0.27 mg/day (IOM 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency; prevention in neonates fed human milk:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm (&lt;37 weeks gestational age): 2 mg/kg/day divided every 12 to 24 hours; begin at 4 to 8 weeks PNA (maximum daily dose: 15 mg/<b>day</b>) (Baker 2010; WHO 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Full-term: In healthy, term infants, that are full or partially breast-fed, AAP does not recommend routine additional supplementation of iron be considered until at least 4 to 6 months of age, if at all (Baker 2010; Schanler 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia; treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment, severe iron deficiency anemia: 4 to 6 mg/kg/day in 3 divided doses (Carney 2010; Rao 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment, mild to moderate iron deficiency anemia: 3 mg/kg/day in 1 to 2 divided doses (CDC 1998; IOM 1993)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1031846\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=polysaccharide-iron-complex-drug-information\" class=\"drug drug_general\">see &quot;Polysaccharide-iron complex: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosages are expressed in terms of <b>elemental</b> iron.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake (AI): </b>Oral: Infants &le;6 months: 0.27 mg/day (IOM 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA)</b> (IOM 2001)<b>:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 7 to 12 months: 11 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 3 years: 7 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 8 years: 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 9 to 13 years: 8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 14 to 18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Male: 11 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Female: 15 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency anemia; prevention: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;4 months (receiving human milk as only nutritional source or &gt;50% as source of nutrition without iron fortified food): 1 mg/kg/day (Baker 2010); <b>Note:</b> In healthy, term infants, AAP does not recommend routine additional supplementation of iron be considered until at least 4 to 6 months of age if breast-fed (full or partial) (Baker 2010; Schanler 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children &lt;2 years in areas where anemia prevalence is &gt;40% and iron fortified foods not available: 2 mg/kg/day (WHO 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years to &lt;5 years in areas where anemia prevalence is &gt;40%: 2 mg/kg/day; maximum daily dose: 30 mg/<b>day </b>(WHO 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years in areas where anemia prevalence is &gt;40%: 30 mg/day with folic acid (WHO 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents in areas where anemia prevalence is &gt;40%: 60 mg/day with folic acid (WHO 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency anemia, treatment: </b>Infants, Children, and Adolescents: Oral: 3 to 6 mg/kg/day in 3 divided doses; suggested maximum daily dose: 200 mg/<b>day</b> (Corkins 2015; Kliegman 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron supplementation:</b> <b>Note</b>: Refer to product-specific labeling for approved pediatric ages.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;4 years: Oral liquid: Oral: 15 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: 50 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA) </b>(IOM 2001): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">19 to 50 years: Males: 8 mg/day; Females: 18 mg/day; Pregnant females: 27 mg/day; Lactating females: 9 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 years: 8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iron deficiency:</b> Oral: 150 to 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosing adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment</b>: There are no dosing adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211207\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EZFE 200: 200 mg [non-toxic; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferrex 150: 150 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #5 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferric x-150: 150 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">iFerex 150: 150 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myferon 150: 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovaFerrum 50: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nu-Iron: 150 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PIC 200: 200 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Poly-Iron 150: 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovaFerrum 125: Polysaccharide-iron complex 125 mg and cholecalciferol 100 units per 5 mL (180 mL) [alcohol free, dye free, gluten free, lactose free, sodium free, sugar free; contains sodium benzoate; raspberry-grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovaFerrum Pediatric Drops: 15 mg/mL (120 mL) [alcohol free, dye free, gluten free, lactose free, sodium free, sugar free; contains sodium benzoate; raspberry-grape flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211198\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20300306\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with water or juice between meals for maximum absorption; may administer with food if GI upset occurs; do not administer with milk or milk products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23887952\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1031839\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention and treatment of iron deficiency anemia (OTC: FDA approved in adults; refer to product-specific labeling for specific information regarding FDA approval in pediatric patients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211226\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, darkening of stools, dental discoloration, diarrhea, epigastric pain, gastrointestinal irritation, heartburn, nausea, stomach cramps, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Local irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23887951\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Known hypersensitivity to polysaccharide-iron complex or any component of the formulations; hemochromatosis; hemosiderosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for other iron-containing products is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11392044\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stool discoloration: Oral iron preparations commonly cause dark or black stools; patients should be informed of the effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. May interfere with absorption of antibiotics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: <b>Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral iron formulations: Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Investigate type of anemia and potential underlying causes (eg, recurrent blood loss) prior to initiating iron supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Excipient: Some formulations may contain tartrazine, which is associated with allergic-type reactions. Although rare, hypersensitivity is more frequently seen in individuals with aspirin allergy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26069852\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Consider all iron sources when evaluating the dose of iron, including combination products, infant formulas, and liquid nutritional supplements.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299906\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222429\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89426&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Iron Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Iron Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Iron Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron salts. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any iron-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Entacapone: Iron Salts may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Salts. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron salts. Therapy with oral iron salts should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the absorption of Iron Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron salts. Therapy with oral iron salts should begin 5 days after the last dose of IV iron isomaltoside.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the absorption of Iron Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Iron Salts may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Iron Salts. Iron Salts may decrease the serum concentration of Trientine. Management: Trientine manufacturer recommends avoiding concurrent use with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used; however, separate administration by at least 2 hours.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6789298\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20300307\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum  iron, total iron binding capacity, reticulocyte count, hemoglobin, ferritin </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20300308\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum  iron: 22 to 184 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total iron binding capacity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 100 to 400 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adults: 250 to 400 mcg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46174594\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hematologic response: Red blood cells form within 3 to 10 days; similar onset as parenteral iron salts; Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Iron is absorbed in the duodenum and upper jejunum; in persons with normal iron stores 10% of an oral dose is absorbed; this is increased to 20% to 30% in persons with inadequate iron stores; food and achlorhydria will decrease absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: To transferrin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine, sweat, sloughing of intestinal mucosa, and by menses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211211\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (EZFE 200 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">434.8 (200 Fe) mg (30): $10.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (iFerex 150 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $33.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (NovaFerrum 50 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (90): $16.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Nu-Iron Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $51.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Poly-Iron 150 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $27.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (NovaFerrum 125 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125-100 mg-unit/5 ml (180 mL): $24.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (NovaFerrum Pediatric Drops Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/mL (120 mL): $22.86</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50708339\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ferricure (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Baker RD, Greer FR, Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). <i>Pediatrics</i>. 2010;126(5):1040-1050.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polysaccharide-iron-complex-pediatric-drug-information/abstract-text/20923825/pubmed\" target=\"_blank\" id=\"20923825\">20923825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States,&quot; <i>MMWR REcomm Rep</i>, 1998, 47(RR-3):1-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corkins M, &ldquo;Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds, <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum.</i> 2nd ed. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EZFE 200 (polysaccharide-iron complex) [prescribing information]. Chattanooga, TN: R.A. McNeil Co; November 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrex 150 (polysaccharide-iron complex) [prescribing information]. Hauppauge, NY: Contract Pharmacal Corp; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, D.C. The National Academies Press, 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM) National Research Council. <i>Iron Deficiency Anemia: Recommended Guidelines for the Prevention, Detection, and Management Among U.S. Children and Women of Childbearing Age. </i>Washington, D.C. The National Academies Press, 1993.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM). <i>Nutrition During Lactation</i>. Washington, D.C. The National Academies Press, 1991. Available at <a href=\"http://www.nap.edu/\" target=\"_blank\">http://www.nap.edu</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NovaFerrum 50 (polysaccharide-iron complex) [prescribing information]. Corpus Christi, TX: Gensavis Pharmaceuticals, LLC; 2012</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NovaFerrum pediatric drops (polysaccharide-iron complex) [prescribing information]. Corpus Christi, TX: Gensavis Pharmaceuticals, LLC; June 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poly-Iron (polysaccharide-iron complex) [prescribing information]. Madison MS: Cypress Pharmaceutical, Inc; March 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rao R, Georgieff MK. Iron therapy for preterm infants. <i>Clin Perinatol</i>. 2009;36(1):27-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polysaccharide-iron-complex-pediatric-drug-information/abstract-text/19161863/pubmed\" target=\"_blank\" id=\"19161863\">19161863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schanler RJ;, Executive Commitee, Feldman-Winter L, et al. Concerns with early universal iron supplementation of breastfeeding infants. <i>Pediatrics</i>. 2011;127(4):e1097.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polysaccharide-iron-complex-pediatric-drug-information/abstract-text/21460097/pubmed\" target=\"_blank\" id=\"21460097\">21460097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    United Nations Children's Fund, United Nations University, World Health Organization. Iron deficiency anaemia assessment, prevention, and control. A guide for programme managers, 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &ldquo;Iron Deficiency Anaemia: Assessment, Prevention, and Control.  A Guide for Programme Managers,&rdquo; 2001.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89426 Version 93.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211213\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1031838\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F49161081\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1031846\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211207\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F211198\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20300306\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F23887952\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1031839\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211226\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F23887951\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11392044\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26069852\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299906\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222429\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6789298\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20300307\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F20300308\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F46174594\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F211211\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50708339\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/89426|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polysaccharide-iron-complex-drug-information\" class=\"drug drug_general\">Polysaccharide-iron complex: Drug information</a></li><li><a href=\"topic.htm?path=polysaccharide-iron-complex-patient-drug-information\" class=\"drug drug_patient\">Polysaccharide-iron complex: Patient drug information</a></li></ul></div></div>","javascript":null}